Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma

World Journal of Gastroenterology

Volumn 20, Issue 18, 2014, Pages 5533-5539

  Zhang, Yan ^a   Zhang, Ya Lou ^a   Chen, Hong Ming ^a   Pu, Hong Wei ^a   Ma, Wen Jing ^a   Li, Xiao Mei ^a   Ma, Hong ^a   Chen, Xiao ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

B cellspecific moloney leukemia virus insert site 1; Esophageal squamous cell carcinoma; Metastasis; Plasminogen activator inhibitor 1; Prognosis

Indexed keywords

BMI1 PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; BMI1 PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; SURVIVAL RATE; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCOMB REPRESSIVE COMPLEX 1; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900428139     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i18.5533     Document Type: Article

References (27)

1. Pu XH, Pu HW, Chen X, Shen QL. Expression and its significance of RASSF1A and FGF3 in esophageal carcinoma. Yixue Yanjiu Zazhi 2010; 27: 11-14 [DOI: 10.3969/j.issn.1674-490X.2010.01.004]
2. Guo WJ, Datta S, Band V, Dimri GP. Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell 2007; 18: 536-546 [PMID: 17151361]
3. Dalley AJ, Pitty LP, Major AG, Abdulmajeed AA, Farah CS. Expression of ABCG2 and Bmi-1 in oral potentially malignant lesions and oral squamous cell carcinoma. Cancer Med 2014; 3: 273-283 [PMID: 24415717 DOI: 10.1002/cam4.182]
4. Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, Song LB, Zeng MS. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer 2011; 10: 10 [PMID: 21276221]
5. Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ, Li SX, Wang XL, Peng ZH. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 2010; 136: 997-1006 [PMID: 20024662]
6. Guo P, Gao A, Zhang G, Han H, Zhou Q. Decoding the knots of initiation of oncogenic epithelial-mesenchymal transition in tumor progression. Curr Cancer Drug Targets 2013; 13: 996-1011 [PMID: 24168183]
7. Yan W, Zhang W, Sun L, Liu Y, You G, Wang Y, Kang C, You Y, Jiang T. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 2011; 1411: 108-115 [PMID: 21831363 DOI: 10.1016/j.brainres.2011.07.002]
8. Choy B, Bandla S, Xia Y, Tan D, Pennathur A, Luketich JD, Godfrey TE, Peters JH, Sun J, Zhou Z. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. BMC Gastroenterol 2012; 12: 146 [PMID: 23078618 DOI: 10.1186/1471-230X-12-14 6]
9. Abd El hafez A, El-Hadaad HA. Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer. Ann Diagn Pathol 2014; 18: 58-62 [PMID: 24342665 DOI: 10.1016/j.anndiagpath.2013.11.004]
10. He XT, Cao XF, Ji L, Zhu B, Lv J, Wang DD, Lu PH, Cui HG. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J Gastroenterol 2009; 15: 2389-2394 [PMID: 19452584 DOI: 10.3748/wjg.15.2389]
11. Qian P, Lu ZX, Yang CX. Determination of the Plasma PAI-1 and Its Clinical Significance in Pancreatic Cancer Patients. Fangshe Mianyixue Zazhi 2012; 25: 559-560 [DOI: 10.3969/ j.issn.1008-9810.2012.05.041]
12. Jiang L, Sun CL, Li H, Yu H. Expression of Smad7, uPA and PAI-1 in pancreatic cancer and its clinical significance. Jiangsu Daxue Xuebao 2010; 20: 527-531 [DOI: 10.3969/j.issn.1671-7783. 2010.06.018]
13. Wu J, Hu D, Yang G, Zhou J, Yang C, Gao Y, Zhu Z. Downregulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells. J Cell Biochem 2011; 112: 1938-1948 [PMID: 21445878 DOI: 10.1002/jcb.23114]
14. Yu J, Lu Y, Cui D, Li E, Zhu Y, Zhao Y, Zhao F, Xia S. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. Oncol Rep 2014; 31: 910-918 [PMID: 24317363 DOI: 10.3892/or.2013.2897]
15. Yu X, Jiang X, Li H, Guo L, Jiang W, Lu SH. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stemlike cells by suppressing stem renewal factor Bmi-1. Stem Cells Dev 2014; 23: 576-585 [PMID: 24219349]
16. Gavrilescu MM, Todosi AM, Aniţei MG, Filip B, Scripcariu V. Expression of bmi-1 protein in cervical, breast and ovarian cancer. Rev Med Chir Soc Med Nat Iasi 2012; 116: 1112-1117 [PMID: 23700898]
17. Xin T, Zhang FB, Sui GJ, Jin XM. Bmi-1 siRNA inhibited ovarian cancer cell line growth and decreased telomerase activity. Br J Biomed Sci 2012; 69: 62-66 [PMID: 22872929]
18. Zhan HB, Cai XG, Wu FM. Expression and clinical significance of Bmi-1 protein and hTERT protein in non-small cell lung cancer. Linchuang Zhongliuxue Zazhi 2009; 14: 4-10 [DOI: 10.3969/j.issn.1009-0460.2009.01.003]
19. Chen Y, Lian G, Zhang Q, Zeng L, Qian C, Chen S, Huang K. Overexpression of Bmi-1 induces the malignant transformation of gastric epithelial cells in vitro. Oncol Res 2013; 21: 33-41 [PMID: 24330850 DOI: 10.3727/096504013X1378665907 0316]
20. Farivar S, Zati Keikha R, Shiari R, Jadali F. Expression of bmi-1 in pediatric brain tumors as a new independent prognostic marker of patient survival. Biomed Res Int 2013; 2013: 192548 [PMID: 23984324 DOI: 10.1155/2013/192548]
21. Allott EH, Morine MJ, Lysaght J, McGarrigle SA, Donohoe CL, Reynolds JV, Roche HM, Pidgeon GP. Elevated Tumor Expression of PAI-1 and SNAI2 in Obese Esophageal Adenocarcinoma Patients and Impact on Prognosis. Clin Transl Gastroenterol 2012; 3: e12 [PMID: 23238211 DOI: 10.1038/ctg.2012.5]
22. Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst 2012; 104: 1470-1484 [PMID: 22984202 DOI: 10.1093/jnci/djs377]
23. Sogutlu Sari E, Yazici A, Eser B, Erol MK, Kilic A, Ermis SS, Koytak A, Akşit H, Yakut T. The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels. Cutan Ocul Toxicol 2014; Epub ahead of print [PMID: 24446892]
24. Zhang J, Gu C, Lawrence DA, Cheung AK, Huang Y. A PAI-1 mutant retards diabetic nephropathy in db/db mice through protecting podocytes. Exp Physiol 2014; Epub ahead of print [PMID: 24443353]
25. Thapa B, Kim YH, Kwon HJ, Kim DS. The LRP1-independent mechanism of PAI-1-induced migration in CpG-ODN activated macrophages. Int J Biochem Cell Biol 2014; 49: 17-25 [PMID: 24440681 DOI: 10.1016/j.biocel.2014.01.008]
26. Kim ER, Yang MH, Lim YJ, Lee JH, Chang DK, Kim YH, Son HJ, Kim JJ, Rhee JC, Kim JY. Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms. Gut Liver 2013; 7: 519-523 [PMID: 24073308 DOI: 10.5009/gnl.2013.7.5.519]
27. Gomes-Giacoia E, Miyake M, Goodison S, Rosser CJ. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther 2013; 12: 2697-2708 [PMID: 24072883 DOI: 10.1158/1535-7163. MCT-13-0500]